The secretary of Health and Human Services nominee wrote in an ethics agreement that he would keep receiving contingency fees.

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Robert F. Kennedy Jr., Trump’s pick to be health secretary, is keeping his financial stake in major vaccine litigation ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...